ArticleOncogene2026
Colony-stimulating factor-2 triggers NNMT-dependent myofibroblast activation in head and neck cancer.
Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Myofibroblastic cancer-associated fibroblasts (myoCAFs) represent a crucial stromal cell subpopulation associated with tumor growth, relapse, and metastasis. In this study, we identify a noncanonical mechanism through which head and neck cancer cells regulate myoCAF activation. Co-culture with tumor organoids promoted the expression of cytokine interaction-related genes and myoCAF phenotypic markers in paracancerous fibroblasts (PFs). Cytokine and tissue array analyses revealed that upregulation of colony-stimulating factor-2 (CSF2) in tumor cells correlated with overexpression of nicotinamide N-methyltransferase (NNMT) in CAFs. Notably, CSF2 treatment enhanced myoCAF properties in a NNMT-dependent manner, while NNMT overexpression remained largely unaffected by transforming growth factor-β (TGF-β). In both assembled organoid and xenograft models, tumor growth was reduced when either CSF2 in cancer cells or CSF2 receptor subunit CSF2RA in CAFs was knocked down. Mechanistically, CSF2 induced FOS phosphorylation at Ser32, promoting nuclear translocation of phosphorylated FOS (p-FOS) to regulate NNMT transcription. In drug screening assays, CSF2 blockade partially overcame resistance to TGF-β inhibition. These findings establish the CSF2/FOS/NNMT axis as a TGF-β-independent pathway driving myoCAF activation.
Indexed as
Identifiers
41896590What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.